Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Central nervous system (CNS) multisynaptic pathways are intricate networks of neurons and interneurons that facilitate the transmission and integration of signals across multiple synapses within the brain and spinal cord (StatPearls: Physiology, Reflexes). These pathways are essential for complex physiological processes, including the coordination of motor output, the processing of sensory information, and the execution of polysynaptic reflex arcs (PubMed, PMID: 11579131). In a clinical context, these pathways are often cited as the functional target for centrally acting muscle relaxants, which aim to reduce hyperactive reflex activity and muscle spasticity by depressing neuronal excitability within these circuits (Goodman & Gilman's The Pharmacological Basis of Therapeutics). The modulation of these pathways is primarily achieved through the manipulation of inhibitory neurotransmitters like gamma-aminobutyric acid (GABA) or through the inhibition of excitatory glutamatergic transmission. For instance, baclofen acts as an agonist at GABA-B receptors located on these multisynaptic circuits, while tizanidine reduces excitatory input by stimulating alpha-2 adrenergic receptors (PubChem, CID: 2284). Because the term encompasses a vast array of different neuronal types and neurotransmitter systems, it represents a physiological or anatomical system rather than a discrete molecular target like a specific receptor or enzyme. Consequently, therapeutic intervention in these pathways often results in non-specific CNS effects, including sedation, dizziness, and impaired motor coordination (NIH, National Institute of Neurological Disorders and Stroke).
Drugs targeting these pathways typically act by enhancing inhibitory neurotransmission (e.g., via GABA receptors) or inhibiting excitatory neurotransmission (e.g., via alpha-2 adrenergic receptors or glutamate inhibition) within the interneuronal circuits of the spinal cord and brainstem (PubMed, PMID: 15182223).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Central nervous system multisynaptic pathways.